Sun Pharmaceutical Industries Limited announced its robust financial performance for the quarter and year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹584,620 million, marking a significant growth, and reported a strong annual net profit of ₹114,794 million. Driven by the growth of its innovative medicines and a solid presence in the Indian market, the company has declared a final dividend of ₹5.00 per share for the fiscal year.
Financial Performance Overview
Sun Pharma demonstrated strong operational performance throughout the fiscal year 2026. For the quarter ended March 31, 2026, consolidated revenue grew to ₹146,117.9 million, representing a 13.6% growth year-over-year. The full-year revenue stood at ₹584,620.4 million, a growth of 11.9% compared to the previous year. Net profit for the year reached ₹114,794.2 million, reflecting the company’s strong operational efficiency and focus on high-growth segments.
Innovative Medicines and Market Growth
The company’s focus on Innovative Medicines continues to yield results, with global sales for this segment reaching USD 1,420 million for the full year, a growth of 16.8%. In the Indian market, formulation sales grew by 14% to ₹192,904 million, supported by a 0.3 percentage point increase in market share. The company remains the number one pharmaceutical company in India by prescription volume.
Strategic Acquisitions and Future Outlook
Sun Pharma is actively expanding its capabilities, most recently entering a definitive agreement to acquire Organon & Co., a move aimed at accelerating its transformation into a leading global pharmaceutical entity. The company continues to maintain a strong balance sheet, ending the year with a net cash position of USD 3.2 billion, while successfully navigating legacy settlement matters and integration projects.
Dividend Announcement
In recognition of the company’s performance, the Board of Directors has recommended a final dividend of ₹5.00 per equity share of ₹1 each for FY2025-26. This is in addition to the interim dividend of ₹11.00 per share already declared and paid, bringing the total dividend for the year to ₹16.00 per share.
Source: BSE
